Paula M Hauck
Overview
Explore the profile of Paula M Hauck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fleisher A, Munsie L, Perahia D, Andersen S, Higgins I, Hauck P, et al.
Neurology
. 2024 Feb;
102(5):e208061.
PMID: 38386949
Background And Objectives: Zagotenemab (LY3303560), a monoclonal antibody that preferentially targets misfolded, extracellular, aggregated tau, was assessed in the PERISCOPE-ALZ phase 2 study to determine its ability to slow cognitive...
2.
Willis B, Lo A, Dage J, Shcherbinin S, Chinchen L, Andersen S, et al.
J Alzheimers Dis Rep
. 2023 Oct;
7(1):1015-1024.
PMID: 37849628
Background: Zagotenemab (LY3303560), a monoclonal antibody, preferentially binds to extracellular, misfolded, aggregated tau that has been implicated in Alzheimer's disease (AD). Objective: The goal of this study was to assess...
3.
Evans C, Sparks J, Andersen S, Brooks D, Hauck P, Mintun M, et al.
Alzheimers Dement
. 2023 May;
19(12):5407-5417.
PMID: 37204338
Introduction: Apolipoprotein E (APOE) ε4 may interact with response to amyloid-targeting therapies. Methods: Aggregate data from trials enrolling participants with amyloid-positive, early symptomatic Alzheimer's disease (AD) were analyzed for disease...
4.
Shcherbinin S, Evans C, Lu M, Andersen S, Pontecorvo M, Willis B, et al.
JAMA Neurol
. 2022 Sep;
79(10):1015-1024.
PMID: 36094645
Importance: β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer disease. Objective: To perform post hoc analyses of amyloid reduction after donanemab treatment and assess its association with tau pathology...
5.
Doty E, Hauck P, Krege J, Komori M, Hake A, Dong Y, et al.
CNS Drugs
. 2022 Jul;
36(7):771-783.
PMID: 35779194
Background: In controlled clinical trials, compared with placebo, a significantly greater proportion of participants using lasmiditan to treat a migraine attack achieved 2-h pain freedom (PF) and experienced ≥ 1...
6.
Bellail A, Jin H, Lo H, Jung S, Hamdouchi C, Kim D, et al.
Sci Transl Med
. 2021 Oct;
13(615):eabh1486.
PMID: 34644148
Discovery of small-molecule degraders that activate ubiquitin ligase–mediated ubiquitination and degradation of targeted oncoproteins in cancer cells has been an elusive therapeutic strategy. Here, we report a cancer cell–based drug...
7.
Lipton R, Baygani S, Tepper S, Krege J, Vasudeva R, Pearlman E, et al.
J Headache Pain
. 2021 Aug;
22(1):101.
PMID: 34454420
Background: While pain freedom at 2 h is a key primary outcome for current trials for acute treatment of migraine, the relationship between the degree of head pain and other...
8.
Martin V, Ahmed Z, Hochstetler H, Baygani S, Dong Y, Hauck P, et al.
Clin Ther
. 2021 Aug;
43(6):1066-1078.
PMID: 34366152
Purpose: Limited information is available on acute treatments for migraine in elderly patients. Our objective was to evaluate the tolerability and safety of lasmiditan, a serotonin 1F agonist, for the...
9.
Clemow D, Baygani S, Hauck P, Hultman C
Curr Med Res Opin
. 2020 Aug;
36(11):1791-1806.
PMID: 32783644
Objective: Determine whether common migraine comorbidities affect the efficacy and safety of lasmiditan, a 5-HT receptor agonist approved in the United States for the acute treatment of migraine. Methods: In...
10.
Hauck P, Wolf E, Olivos 3rd D, McAtarsney C, Mayo L
Oncotarget
. 2017 Dec;
8(61):104455-104466.
PMID: 29262653
Mouse double minute 2 (Mdm2) and MdmX dimerize in response to low levels of genotoxic stress to function in a ubiquitinating complex, which signals for destabilization of p53. Under growth...